(1) SCH 58261 (an A2AR antagonist) was microinjected into the rVLM of EA-treated DSHRs (n = 9). The vehicle (DMSO) was administered into other sites of the rVLM in random order in five of these nine animals. (2) The rVLM of DSHRs treated with sham-EA (n = 9) was administered with CGS-21680 (an A2AR agonist). The vehicle (DMSO) was randomly microinjected into the different rVLM sites in five of the nine rats. (3) In separate rats in normotensive groups, SCH 58261 and its vehicle (n = 4) or CGS-21680 and its vehicle (n = 4) were microinjected into different sites of the rVLM in random order.
Free full text: Click here